Form 4 for BVS Bioventus Inc.
Accepted 2023-04-21 00:00:00 ET · period of report 2022-04-01 · accession 0001578563-23-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-04-21 | 2022-04-01+ | BVS | Nosenzo John | Fmr. Chief Commercial Off | S - Sale | $8.81 | -142 | 87.2K | -0.2% | -$1,251 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-04-01 | S | D | 40 | $14.07 | 87,250 | D | — | — | (F2) Includes an aggregate of 3,398 shares of Class A common stock purchased under the Company's 2021 Employee Stock Purchase Plan. This number has also been adjusted to account for a scrivener's error in a prior filing which attributed an acquisition of 40 shares under the Company's 2021 Employee Stock Purchase Plan. |
| 2 | Common | Class A Common Stock | 2022-10-03 | S | D | 7 | $7.00 | 87,148 | D | — | — | |
| 3 | Common | Class A Common Stock | 2022-07-01 | S | D | 95 | $6.73 | 87,155 | D | — | — |